Zenith Drugs
ZENITHDRUG NSE
Zenith Drugs
HealthcareNSE: ZENITHDRUG Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹79.48 Cr
Volatility
Moderate
P/E Ratio
20.1
EBITDA
₹19.00 Cr
Return on Equity
15.48%
Debt to Equity
0.73
Book Value
₹43.69
52W High
₹73.45
52W Low
₹33.3
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 1.10 times its book value
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Earnings include an other income of Rs.4.88 Cr.
- Company has high debtors of 156 days.
Growth Rate
Revenue Growth
15.46% higher than
3Y
Net Income Growth
95.92% higher than
3Y
Cash Flow Change
-173% higher than
3Y
ROE
-43.75% lower than
3Y
ROCE
-32.19% lower than
3Y
EBITDA Margin (Avg.)
60.07% lower than
3Y
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 69 | 62 | 68 | 66 | 78 | 93 |
| Expenses | 58 | 56 | 61 | 59 | 72 | 87 |
| Operating Profit | 11 | 6 | 7 | 7 | 6 | 6 |
| OPM % | 16% | 9% | 10% | 10% | 8% | 6% |
| Other Income | -1 | 2 | 1 | 1 | 2 | 3 |
| Interest | 1 | 2 | 1 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 2 | 3 | 3 |
| PBT | 8 | 6 | 6 | 4 | 2 | 3 |
| Tax % | 25% | 32% | 0% | 59% | 0% | 48% |
| Net Profit | 6 | 4 | 6 | 1 | 2 | 2 |
| EPS in Rs | 4.75 | 2.24 | 3.34 | 0.84 | 1.36 | 0.94 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 78 | 72 | 92 | 115 | 131 | 132 | 171 |
| Expenses | 71 | 64 | 85 | 105 | 114 | 119 | 159 |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 | 12 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% | 7% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 6 |
| PBT | 5 | 5 | 4 | 7 | 13 | 9 | 5 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% | 27% |
| Net Profit | 3 | 3 | 3 | 5 | 10 | 7 | 4 |
| EPS in Rs | — | — | — | — | 5.56 | 4.18 | 2.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.4 | 0.4 | 0.4 | 0.4 | 17 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 | 58 |
| Borrowings | 12 | 15 | 17 | 25 | 24 | 49 | 55 |
| Other Liabilities | 25 | 21 | 37 | 54 | 48 | 44 | 57 |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| Fixed Assets | 6 | 9 | 10 | 11 | 11 | 40 | 41 |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 37 | 56 | 86 | 119 | 118 | 136 |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | -1 | 5 | -4 | -16 | -5 | 9 |
| Investing | -5 | -2 | -3 | -2 | -5 | -31 | -14 |
| Financing | 1 | 3 | -1 | 6 | 30 | 28 | 5 |
| Net Cash Flow | 0 | 0 | 1 | 0 | 9 | -8 | 0 |
| Free Cash Flow | -1 | -2 | 2 | -6 | -21 | -37 | -5 |
| CFO/OP | 71 | 7 | 88 | -27 | -70 | -25 | 86 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 188 | 167 | 156 |
| Inventory Days | 29 | 52 | 61 | — | 249 | 277 | 126 |
| Days Payable | 155 | 155 | 173 | — | 412 | 281 | 166 |
| Cash Conversion Cycle | -7 | 17 | 16 | 157 | 25 | 163 | 117 |
| Working Capital Days | 14 | 24 | 21 | 39 | 111 | 98 | 77 |
| ROCE % | — | 28% | 24% | 25% | 28% | 13% | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zenith Drugs insights
29 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Copy of Newspaper Publication
8 Sep - Unreadable newspaper OCR; company announcement not identifiable. 8 Sep - Unreadable newspaper OCR; company announcement not identifiable.
2
Outcome of Board Meeting
5 Sep - Board approved 26th AGM notice for 29 Sept 2026 and appointed secretarial auditor, scrutinizer. 5 Sep - Board approved 26th AGM notice for 29 Sept 2026 and appointed secretarial auditor, scrutinizer.
3
Shareholders meeting
5 Sep - 26th AGM on September 29, 2026; approvals sought for audited accounts, borrowing up to ₹200 crore, and director remuneration. 5 Sep - 26th AGM on September 29, 2026; approvals sought for audited accounts, borrowing up to ₹200 crore, and director remuneration.
4
Outcome of Board Meeting
26 Aug - Board approved promoter warrant allotment of 16,09,050 at Rs.43.50 on August 26, 2026; director re-designated. 26 Aug - Board approved promoter warrant allotment of 16,09,050 at Rs.43.50 on August 26, 2026; director re-designated.
5
Outcome of Board Meeting
26 Aug - Board approved Ajay Singh Dassundi’s re-designation and allotment of 16,09,050 warrants for Rs. 6.99 crore on August 26, 2026. 26 Aug - Board approved Ajay Singh Dassundi’s re-designation and allotment of 16,09,050 warrants for Rs. 6.99 crore on August 26, 2026.
Frequently Asked Questions about Zenith Drugs
What does Zenith Drugs Ltd do?
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing
and trading of medicines[1]
Where is Zenith Drugs Ltd (ZENITHDRUG) listed?
Zenith Drugs Ltd trades as ZENITHDRUG on the NSE.
Which sector does Zenith Drugs Ltd belong to?
Zenith Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Zenith Drugs Ltd?
Zenith Drugs Ltd has a market capitalisation of ₹79.48 Cr, which places it in the Small Cap band.
What is the PE ratio of Zenith Drugs Ltd?
Zenith Drugs Ltd trades at a PE ratio of 20.10, against a book value of ₹43.69 per share.
What is the 52-week high and low of Zenith Drugs Ltd?
Over the last 52 weeks Zenith Drugs Ltd has traded between ₹33.3 and ₹73.45.
Does Zenith Drugs Ltd pay dividends?
Zenith Drugs Ltd has a dividend yield of 1.08%.
What is the Return on Equity (ROE) of Zenith Drugs Ltd?
Zenith Drugs Ltd reported a return on equity of 15.48%. Its debt-to-equity ratio is 0.73.
Company Information
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing and trading of medicines[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZENITHDRUG.md for Zenith Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.